Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.210
+0.760 (22.03%)
At close: Aug 3, 2026, 4:00 PM EDT
4.300
+0.090 (2.14%)
After-hours: Aug 3, 2026, 7:31 PM EDT
Camp4 Therapeutics Employees
Camp4 Therapeutics had 48 employees as of December 31, 2025. The number of employees decreased by 7 or -12.73% compared to the previous year.
Employees
48
Change (1Y)
-7
Growth (1Y)
-12.73%
Revenue / Employee
$81,958
Profits / Employee
-$1,797,938
Market Cap
218.61M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 48 | -7 | -12.73% |
| Dec 31, 2024 | 55 | -9 | -14.06% |
| Sep 30, 2024 | 53 | -11 | -17.19% |
| Jun 30, 2024 | 58 | - | - |
| Dec 31, 2023 | 64 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Humacyte | 184 |
| Voyager Therapeutics | 141 |
| MediWound | 121 |
| Immunic | 95 |
| Alpha Cognition | 71 |
| Precision BioSciences | 66 |
| NovaBridge Biosciences | 30 |
CAMP News
- 7 days ago - Camp4 Therapeutics receives Australia TGA clearance for CMP-002 trial - TheFly
- 7 days ago - CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder - GlobeNewsWire
- 17 days ago - CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board - TheFly
- 6 weeks ago - CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Camp4 Therapeutics upgraded to Overweight from Neutral at JPMorgan - TheFly
- 7 weeks ago - Camp4 Therapeutics Transcript: AGM 2026 - Transcripts
- 7 weeks ago - Camp4 Therapeutics initiated with a Buy at Chardan - TheFly